The Cancer Drug Development Forum – CDDF is the platform for all stakeholders involved in the development of cancer drugs.

CDDF Webinar – Patient Access to Newly Registered Anticancer Agents


The Cancer Drug Development Forum held a live webinar, Patient Access to Newly Registered Anticancer Agents on Wednesday 9 December 2020 from 18:30 – 19:30 (CET) / 12:30 – 13:30 (EST) / 9:30 – 10:30 (PST). This live webinar comprised a 25-minute lecture given by Prof. Carin Uyl-de Groot (Erasmus University Rotterdam) followed by Prof. Francesco de Lorenzo (CDDF)’s 5-minute position statement and a 25-minute discussion session.



Many new cancer medicines have been developed that can improve patients’ outcomes. However, access to these agents usually takes longer in Europe than in the United States (US), and varies greatly across EU countries.

The aim of this webinar was to discuss the actual access to several recently registered cancer drugs in European countries following EMA marketing authorisation, and the implications for patients. Prof. Carin Uyl-de Groot will present her most recent research (Uyl-de Groot et cl.,2020) and discuss her findings. Professor Francesco DeLorenzo will comment on the patient’s perspective.

During a Q&A session, participants had the opportunity to further discuss how to improve the health outcomes of European patients and enable faster and more general use of new drugs within Europe.



  • Wednesday 9 December 2020
  • 18:30 – 19:30 (CET) / 12:30 – 13:30 (EST) / 9:30 – 10:30 (PST)



Carin A. Uyl-de Groot (1966) is Professor of Health Technology Assessment at the Erasmus University Rotterdam, the Netherlands. She is head of the section of Health Technology Assessment (HTA) of the Erasmus School of Health Policy&Management and director of the institute for Medical Technology Assessment (iMTA b.v.).  She has been programme leader of cancer studies at the iMTA since 1994. She was chair of the Dutch Foundation of Technology Assessment in Health Care from 2011-2016. In 2014 she has been co-chair of the 17th European Congress of the International Society for PharmacoEconomic Outcomes Research (ISPOR) in Amsterdam. In 2018, she was chair to the public health and health economics track of the European Society of Medical Oncology (ESMO) conference in Munich.

Furthermore, she served as a member of the Dutch Committee on Expensive Cancer Drugs (CieBOM). Since September 2015 she is a member of the Dutch Health Council.

She has presented her research in a variety of clinical and health economic journals, including Lancet Oncology, Nature Reviews, Journal of Clinical Oncology and Blood, and conferences. Her research activities are mainly focused on cost-effectiveness analyses of cancer diagnostics and treatments. Quality of life studies are an integral part of these studies. Her main interest consists of diagnostics and therapeutic technologies, economic studies linked to clinical studies, modelling studies, cost studies, quality of life studies, real world outcomes, methodological issues and implementation studies particularly in the cancer field. She is principal investigator of several cancer registries and outcomes studies (a.o, PHAROS (haematology), PERCEPTION (renal cell cancer), POSEIDON (lung cancer),CAPRI (prostate cancer), melanoma, colon cancer and head&neck cancer. She is supervisor of PhD students and serves as a reviewer for several (high impact) journals.







  • 18:30 – 18:35 (CET): Introduction (Prof. Jaap Verweij)
  • 18:35 – 19:00 (CET): Lecture (Prof. Carin Uyl-de Groot)
  • 19:00 – 19:10 (CET): Patient’s perspective (Prof. Francesco de Lorenzo)
  • 19:10 – 19:30 (CET): Q&A / discussion session (Prof. Jaap Verweij & Prof. Catarina Edfjäll)


Meeting Materials



Cancer Drug Development Forum asbl
Registered office: c/o BLSI, Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium
Register of legal entities: the French Speaking Enterprise Court in Brussels
Enterprise number: 738.523.752
Tel: +32 2 880 62 70